Targeting activated platelets and fibrinolysis: Hitting two birds with one stone

Circulation Research

Volumn 114, Issue 7, 2014, Pages 1070-1073

  Reheman, Adili ^a,d   Xu, Xiaohong ^a,b,d   Reddy, Emily C ^a,d   Ni, Heyu ^a,b,c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d Toronto Platelet Immunobiology Group   (Canada)

^e CANADIAN BLOOD SERVICES   (Canada)

Author keywords

blood platelets; Editorials; fibrinolysis; thrombolytic therapy; thrombosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; MONOCLONAL ANTIBODY; SNAKE VENOM; STREPTOKINASE; THROMBIN INHIBITOR; UROKINASE; VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; BRAIN ISCHEMIA; CLINICAL PRACTICE; DRUG HALF LIFE; FIBRIN FORMATION; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; FOAM CELL; HEALTH CARE QUALITY; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

BLOOD PLATELETS; EDITORIALS; FIBRINOLYSIS; THROMBOLYTIC THERAPY; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; CAROTID ARTERIES; FIBRINOLYTIC AGENTS; SINGLE-CHAIN ANTIBODIES; THROMBOEMBOLISM; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84897517457     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.114.303600     Document Type: Review

References (31)

1. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:399-410.
2. Wang X, Palasubramaniam J, Gkanatsas Y, Hohmann JD, Westein E, Kanojia R, Alt K, Huang D, Jia F, Ahrens I, Medcalf RL, Peter K, Hagemeyer CE. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res. 2014;114:1083-1093.
3. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
4. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503-516.
5. Li C, Li J, Li Y, Lang S, Yougbare I, Zhu G, Chen P, Ni H. Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries. Adv Hematol. 2012;2012:384685.
6. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23:2131-2137.
7. Henn V, Slupsky JR, Gräfe M, Anagnostopoulos I, Förster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
8. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, Ratliff TL. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity. 2003;19:9-19.
9. Lindemann S, Krämer B, Seizer P, Gawaz M. Platelets, inflammation and atherosclerosis. J Thromb Haemost. 2007;5(Suppl 1):203-211.
10. Murphy AJ, Bijl N, Yvan-Charvet L, Welch CB, Bhagwat N, Reheman A, Wang Y, Shaw JA, Levine RL, Ni H, Tall AR, Wang N. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med. 2013;19:586-594.
11. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385-392.
12. Yang H, Reheman A, Chen P, Zhu G, Hynes RO, Freedman J, Wagner DD, Ni H. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost. 2006;4:2230-2237.
13. Reheman A, Yang H, Zhu G, Jin W, He F, Spring CM, Bai X, Gross PL, Freedman J, Ni H. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood. 2009;113:1809-1817.
14. Leung R, Gwozdz AM, Wang H, Bang KW, Packham MA, Freedman J, Rand ML. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activity. J Thromb Haemost. 2007;5:560-570.
15. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin S.R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature. 2001;413:74-78.
16. Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV Jr, Tam C, Coughlin S.R. A dual thrombin receptor system for platelet activation. Nature. 1998;394:690-694.
17. Vu TK, Hung DT, Wheaton VI, Coughlin S.R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
18. Ni H, Papalia JM, Degen JL, Wagner DD. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood. 2003;102:3609-3614.
19. Lei X, Reheman A, Hou Y, Zhou H, Wang Y, Marshall AH, Liang C, Dai X, Li BX, Vanhoorelbeke K, Ni H. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost. 2014;111:279-289.
20. Fang X, Fang Y, Liu L, Liu G, Wu J. Mapping paratope on antithrombotic antibody 6B4 to epitope on platelet glycoprotein Ibalpha via molecular dynamic simulations. PLoS One. 2012;7:e42263.
21. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121:1523-1532.
22. Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol. 2009;29:1151-1155.
23. Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol. 2011;7:400-409.
24. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation. 1999;99:3050-3055.
25. Bledzka K, Smyth SS, Plow EF. Integrin alphaiibbeta3: From discovery to efficacious therapeutic target. Circulation research. 2013;112:1189-1200.
26. Korin N, Kanapathipillai M, Matthews BD, Crescente M, Brill A, Mammoto T, Ghosh K, Jurek S, Bencherif SA, Bhatta D, Coskun AU, Feldman CL, Wagner DD, Ingber DE. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science. 2012;337:738-742.
27. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res. 2006;99:25-33.
28. Schwarz M, Röttgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, Büttner C, Little M, Bode C, Peter K. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. FASEB J. 2004;18:1704-1706.
29. Hagemeyer CE, von Zur Muhlen C, von Elverfeldt D, Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost. 2009;101:1012-1019.
30. Mohapatra S, Cao Y, Ni H, Salo D. In pursuit of the "holy grail": recombinant allergens and peptides as catalysts for the allergen-specific immunotherapy. Allergy. 1995;50:37-44.
31. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086-1095.